Printify
adidas Women's Fleece Joggers (Purple Ribbon Classic)
adidas Women's Fleece Joggers (Purple Ribbon Classic)
Couldn't load pickup availability
Step into comfort with a purpose with these adidas® fleece joggers, designed for those who value both style and sustainability. Made from a blend of 70% Better Cotton Initiative (BCI) cotton and 30% recycled polyester, these joggers bring you a soft, cozy feel with every wear. Dark Grey Heather comes in a unique fabric mix of 55% polyester and 45% cotton, offering the same sustainable quality in a versatile hue.
Complete with convenient side and back-right pockets, a cuffed hem for a snug fit, and the iconic adidas logo on the right hip, these joggers are both functional and effortlessly stylish. Whether you’re lounging or on the move, they offer wardrobe staples you can feel good about.
40% of revenue from each pair supports pancreatic cancer research, so every purchase helps fund vital efforts in the fight against cancer. Embrace comfort with impact—wear your support.
- Sustainable fabric: 70% BCI cotton, 30% recycled polyester (fiber content varies by color)
- Medium-heavy weight (8.5 oz/yd² or 300 g/m²) for all-day comfort
- Regular fit with sewn-in label
- adidas® logo on the right hip
- Printed using Direct to Film (DTF) technology
Share



Recent News
View all-
Phase 1/2 Trial Launches for Innovative Pancrea...
UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...
Phase 1/2 Trial Launches for Innovative Pancrea...
UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...
-
FDA Approves NALIRIFOX as First-Line Treatment ...
New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...
FDA Approves NALIRIFOX as First-Line Treatment ...
New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...
-
Immunotherapy for Pancreatic Ductal Adenocarcin...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...
Immunotherapy for Pancreatic Ductal Adenocarcin...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...